Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu Province, China.
J Headache Pain. 2018 May 29;19(1):42. doi: 10.1186/s10194-018-0868-9.
Migraine is now ranked as the second most disabling disorder worldwide reported by the Global Burden of Disease Study 2016. As a noninvasive neurostimulation technique, transcutaneous electrical nerve stimulation(TENS) has been applied as an abortive and prophylactic treatment for migraine recently. We conduct this meta-analysis to analyze the effectiveness and safety of TENS on migraineurs.
We searched Medline (via PubMed), Embase, the Cochrane Library and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials, which compared the effect of TENS with sham TENS on migraineurs. Data were extracted and methodological quality assessed independently by two reviewers. Change in the number of monthly headache days, responder rate, painkiller intake, adverse events and satisfaction were extracted as outcome.
Four studies were included in the quantitative analysis with 161 migraine patients in real TENS group and 115 in sham TENS group. We found significant reduction of monthly headache days (SMD: -0.48; 95% CI: -0.73 to - 0.23; P < 0.001) and painkiller intake (SMD: -0.78; 95% CI: -1.14 to - 0.42; P < 0.001). Responder rate (RR: 4.05; 95% CI: 2.06 to 7.97; P < 0.001) and satisfaction (RR: 1.85; 95% CI: 1.31 to 2,61; P < 0.001) were significantly increased compared with sham TENS.
This meta-analysis suggests that TENS may serve as an effective and well-tolerated alternative for migraineurs. However, low quality of evidence prevents us from reaching definitive conclusions. Future well-designed RCTs are necessary to confirm and update the findings of this analysis.
Our PROSPERO protocol registration number: CRD42018085984 . Registered 30 January 2018.
全球疾病负担研究 2016 年报告称,偏头痛现在是全球排名第二的致残性疾病。经皮神经电刺激(TENS)作为一种非侵入性神经刺激技术,最近已被用作偏头痛的发作性和预防性治疗。我们进行这项荟萃分析,旨在分析 TENS 对偏头痛患者的有效性和安全性。
我们检索了 Medline(通过 PubMed)、Embase、Cochrane 图书馆和 Cochrane 对照试验中心,以确定比较 TENS 与假 TENS 对偏头痛患者影响的随机对照试验。数据由两位评审员独立提取和评估方法学质量。提取每月头痛天数的变化、应答率、止痛药摄入、不良反应和满意度作为结局。
四项研究被纳入定量分析,真实 TENS 组 161 例偏头痛患者,假 TENS 组 115 例。我们发现每月头痛天数显著减少(SMD:-0.48;95%CI:-0.73 至 -0.23;P<0.001),止痛药摄入也显著减少(SMD:-0.78;95%CI:-1.14 至 -0.42;P<0.001)。与假 TENS 相比,应答率(RR:4.05;95%CI:2.06 至 7.97;P<0.001)和满意度(RR:1.85;95%CI:1.31 至 2.61;P<0.001)显著增加。
这项荟萃分析表明,TENS 可能成为偏头痛患者的一种有效且耐受良好的替代治疗方法。然而,由于证据质量较低,我们无法得出明确的结论。未来需要进行设计良好的 RCT 来证实和更新本分析的结果。
我们的 PROSPERO 方案注册编号:CRD42018085984。于 2018 年 1 月 30 日注册。